Claims for Patent: 10,583,130

Summary for Patent: 10,583,130

Title:	Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof
Abstract:	The present disclosure relates to compositions and pharmaceutical formulations comprising at least one active pharmaceutical ingredient chosen from nitrocatechol derivatives of formula I as defined herein and salts, esters, hydrates, solvates and derivatives thereof and methods of making said compositions and pharmaceutical formulations.
Inventor(s):	de Vasconcelos; Teofilo Cardoso (Sao Mamede do Coronado, PT), dos Santos Lima; Ricardo Jorge (Sao Mamede do Coronado, PT), de Campos Costa; Rui Cerdeira (Sao Mamede do Coronado, PT)
Assignee:	BIAL-PORTELA & CA, S.A. (S. Mamede do Coronado, PT)
Application Number:	16/050,602
Patent Claims:	1. A method of treating Parkinson's disease, parkinsonian disorders, or restless leg syndrome, said method comprising administering a composition comprising granules comprising 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide to a patient, wherein the composition has a bulk density greater than 0.2 g/mL. 2. The method according to claim 1, wherein the disorder is chosen from Parkinson's disease. 3. The method according to claim 1, wherein the composition further comprises 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5- -yl]-3-nitrobenzene-1,2-diol. 4. The method according to claim 3, wherein the ratio of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide to the 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nit- robenzene-1,2-diol ranges from about 99:1 to about 95:5. 5. The method according to claim 3, wherein the 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nit- robenzene-1,2-diol is present in an amount up to about 5% by weight, relative to the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide. 6. The method according to claim 3, further comprising at least one additional component chosen from fillers, diluents, binders, disintegrants, lubricants, and glidants. 7. The method according to claim 3, wherein the bulk density of the composition is greater than 0.3 g/mL. 8. A method of treating Parkinson's disease, parkinsonian disorders, or restless leg syndrome, the method comprising administering a pharmaceutical formulation comprising a composition comprising granules comprising 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide to a patient, wherein the composition has a bulk density greater than 0.2 g/mL. 9. The method according to claim 8, wherein the disorder is chosen from Parkinson's disease. 10. The method according to claim 8, wherein the formulation is a dosage form chosen from tablets and capsules. 11. The method according to claim 8, wherein the formulation is a capsule. 12. The method according to claim 8, wherein the total amount of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide is at least 10 mg. 13. The method according to claim 8, wherein the composition further comprises 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5- -yl]-3-nitrobenzene-1,2-diol. 14. The method according to claim 13, wherein the formulation is a dosage form chosen from tablets and capsules. 15. The method according to claim 13, wherein the formulation is a capsule. 16. The method according to claim 13, wherein the total amount of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide and the 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nit- robenzene-1,2-diol is at least 10 mg. 17. The method according to claim 8, wherein the total amount of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide is at least 20 mg. 18. The method according to claim 8, wherein the total amount of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide is at least 50 mg. 19. The method according to claim 8, wherein the total amount of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide is about 25 mg. 20. The method according to claim 8, wherein the total amount of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide is about 50 mg. 21. The method according to claim 13, wherein the total amount of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide and the 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nit- robenzene-1,2-diol is at least 20 mg. 22. The method according to claim 13, wherein the total amount of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide and the 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nit- robenzene-1,2-diol is at least 50 mg. 23. The method according to claim 13, wherein the total amount of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide and the 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nit- robenzene-1,2-diol is about 25 mg. 24. The method according to claim 13, wherein the total amount of the 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6- -dimethylpyridine 1-oxide and the 5-[3-(2,5-dichloro-4,6-dimethylpyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nit- robenzene-1,2-diol is about 50 mg.